Factors affecting %CDT status at entry into a multisite clinical treatment trial: experience from the COMBINE Study.
BACKGROUND
Carbohydrate-deficient transferrin (CDT) occurs as a higher percentage of normal transferrin (%CDT) in heavy drinkers. %CDT is used as a marker of both alcohol use disorder severity and treatment outcome both clinically and in treatment trials. Nevertheless, little is known about the parameters that predict which patients are %CDT positives at treatment entry. These parameters might include level of drinking, days of abstinence before testing, and severity of alcohol dependence before evaluation.


METHODS
%CDT levels were collected before randomization from participants of the COMBINE Study, a large federally sponsored multisite clinical trial evaluating medications and behavioral therapies in alcohol-dependent outpatients. %CDT (assayed in a central laboratory) was available in 1,193 individuals for whom drinking history in the 30 days before testing and measures of alcoholism severity were documented. The effects of drinking history and alcohol severity were evaluated for prediction of a %CDT-positive test status.


RESULTS
Less percent days abstinent (PDA) and more drinks per drinking day (DDD) were predictive of higher rates of %CDT-positive patients (maximum 67%). Up to 14 days of continuous abstinence before testing did not appear to significantly affect %CDT status. Rates of %CDT positives remained reasonably steady up to about 40% PDA. Years of drinking at dependence levels had an unexpected negative impact on %CDT-positive rates while previous treatment had a small but positive impact of %CDT-positive rates. ADS and DrInC scores had no predictive value over and above recent drinking amounts on %CDT status.


CONCLUSIONS
%CDT is more likely to be positive in those who have more days of drinking and to a lesser degree in those who drink more per drinking day. It can remain positive even in those alcoholic subjects who stop drinking many days before testing. Alcoholic subjects with more treatment experiences appear to have a marginally higher %CDT-positive rate.
Anton
Raymond F
RF
Medical University of South Carolina, and Center for Drug and Alcohol Problems, 67 President Street, Charleston, SC 29425, USA. antonr@musc.edu
Youngblood
Marston
M
D000328:Adult; D000437:Alcoholism / Q000097:blood* / Q000523:psychology / Q000534:rehabilitation*; D002492:Central Nervous System Depressants / Q000097:blood; D000431:Ethanol / Q000097:blood; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D011569:Psychiatric Status Rating Scales; D013695:Temperance; D014168:Transferrin / Q000031:analogs & derivatives* / Q000378:metabolism*
D002492:Central Nervous System Depressants; D014168:Transferrin; C056759:carbohydrate-deficient transferrin; D000431:Ethanol